About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

Risk Management Options

  • Basics

Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group
Timothy R. Rebbeck, Tara Friebel, Theresa Wagner, Henry T. Lynch, Judy E. Garber, Mary B. Daly, Claudine Isaacs, Olufunmilayo I. Olopade, Susan L. Neuhausen, Laura van 't Veer, Rosalind Eeles , D. Gareth Evans, Gail Tomlinson, Ellen Matloff, Steven A. Narod, Andrea Eisen, Susan Domchek, Katrina Armstrong, and Barbara L. Weber. Journal of Clinical Oncology, (Published on-line ahead of print).,October 2005.

Safety and Efficacy of a Testosterone Patch for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Glenn D. Braunstein, Dale A. Sundwall, Molly Katz, Jan L. Shifren, John E. Buster, James A. Simon, Gloria Bachman, Oscar A. Aguirre, Johna D. Lucas, Cynthia Rodenberg, Akshay Buch, Nelson B. Watts. Archives of Internal Medicine, Volume 165 Number 14: p. 1582-1589, July 2005.

Effect of Zolpidem on sleep in women with perimenopausal and postmenopausal insomnia: a 4-week, randomized, multicenter, double-blind, placebo-controlled study
Cynthia M. Dorsey, Kathryn A. Lee, Martin B. Scharf. Clinical Therapeutics, Volume 26, Issue 10: p. 1578-1586, October 2004.

BRCA germline mutations in Jewish women with uterine serous papillary carcinoma
Ofer Lavie, Gila Hornreich, Alon Ben-Arie, Gad Rennert, Yoram Cohen, Rehuven Keidar, Shlomi Sagi, Efrat Levy Lahad, Ron Auslander, Uzi Beller. Gynecologic Oncology, Volume 92, Number 2: p. 521-524, February 2004.

Phase III Evaluation of Fluoxetine for Treatment of Hot Flashes
Charles L. Loprinzi, Jeff A. Sloan, Edith A. Perez, Susan K. Quella, Phillip J. Stella, James A. Mailliard, Michele Y. Halyard, Sandhya Pruthi, Paul J. Novotny, Teresa A. Rummans. Journal of Clinical Oncology, Volume 20, Issue 6: p. 1578-1583, March 2002.

Natural Hormone Replacement Therapy: What It Is and What Consumers Really Want
Dana Reed-Kane, PharmD, FIACP, FACA. International Journal of Pharmaceutical Compounding, Volume 5, Number 5: p. 332-335, September/October 2001.

Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study
Steven A Narod, Ping Sun, Parviz Ghadirian, Henry Lynch, Claudine Isaacs, Judy Garber, Barbara Weber, Beth Karlan, David Fishman, Barry Rosen, Nadine Tung, Susan L Neuhausen. Lancet, Volume 12, Issue 357(9267): p. 1467-70, May 2001.

Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us


This site has been made possible by a generous grant from Morphotek.

Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org